← Back to Search

Mesdopetam for Parkinson's Disease

Phase 2
Waitlist Available
Research Sponsored by Integrative Research Laboratories AB
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to end of treatment (week 12)
Awards & highlights

Summary

This trial is testing mesdopetam, a medication, to help people with Parkinson's disease. The goal is to see if it can increase the time patients feel well without experiencing troublesome movements. Patients will take the medication for a few months, and their symptoms will be closely monitored. Mesdopetam is a new treatment developed for managing complications of Parkinson's disease therapy, such as involuntary movements and psychosis.

Eligible Conditions
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to end of treatment (week 12)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to end of treatment (week 12) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia With Mesdopetam Compared to Placebo as Assessed With 24-hour Patient Home Diaries From Baseline to End of Treatment.
Secondary study objectives
Change From Baseline in Average Daily Hours of OFF-time (With Mesdopetam Compared to Placebo).
Change From Baseline in Mean Score of Disability Associated With ON-phase Dyskinesia Assessed With the Sum Score of Parts 1b and 4 of the Unified Dyskinesia Rating Scale (UDysRS), With Mesdopetam Compared to Placebo.
Change From Baseline in Mean Score of Motor Symptoms of PD Assessed With MDS-UPDRS Total Score of Part 2 (M-EDL) (With Mesdopetam Compared to Placebo)
+1 more

Side effects data

From 2022 Phase 2 trial • 155 Patients • NCT04435431
11%
Mobility decreased
5%
Parkinsonism
3%
Fall
3%
Dyskinesia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Mesdopetam 5 mg
Mesdopetam 7.5 mg
Mesdopetam 2.5 mg
Placebo

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Mesdopetam dose 3Experimental Treatment1 Intervention
Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.
Group II: Mesdopetam dose 2Experimental Treatment1 Intervention
Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.
Group III: Mesdopetam dose 1Experimental Treatment1 Intervention
Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
Group IV: PlaceboPlacebo Group1 Intervention
Placebo capsule, 1 capsule b.i.d. for 84 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mesdopetam
2020
Completed Phase 2
~160

Find a Location

Who is running the clinical trial?

Integrative Research Laboratories ABLead Sponsor
4 Previous Clinical Trials
337 Total Patients Enrolled
Joakim TedroffStudy DirectorIntegrative Research Laboratories AB (IRLAB)
1 Previous Clinical Trials
165 Total Patients Enrolled
~32 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top